secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001558370-23-018581
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports Q3 net loss $3.2M; cash $25.4M; ATRN-1051 IND on track for Q4 2023
--------------------------------------------------------------------------------

- Net loss of $3.2M ($0.86/sh) vs $4.0M ($2.32/sh) in Q3 2022; operating loss reduced to $3.5M.
- Cash and equivalents $25.4M as of Sep 30, 2023; cash runway through Q4 2024.
- ATRN-119 dose escalation at cohort 4 (350mg); dose expansion enrollment expected Q2 2024.
- ATRN-1051 IND submission planned Q4 2023 with clearance Q1 2024; Phase 1/2a start H1 2024.
- R&D expenses $2.1M (up from $1.1M) due to ATRN-1051 IND studies; G&A down to $1.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/0001558370-23-018581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/apre-20231109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer